Core Insights - INmune Bio Inc. presented significant findings on the effects of XPro™ on synaptic proteins and pathways at the Alzheimer's Association International Conference (AAIC) [1][2] - The analysis showed that a 12-week treatment with XPro™ led to notable changes in synaptic proteins crucial for neuron communication [2][3] - The company is currently conducting a phase 2 clinical trial for mild to moderate Alzheimer's patients, with top-line results expected in early 2025 [4] Company Overview - INmune Bio Inc. is a clinical-stage company focused on inflammation and immunology, developing treatments that leverage the innate immune system [1][6] - The company has two main product platforms in clinical trials: the Dominant-Negative Tumor Necrosis Factor (DNTNF) platform and the Natural Killer Cell Priming Platform [6] - XPro™ is a next-generation TNF inhibitor that neutralizes soluble TNF without affecting trans-membrane TNF or TNF receptors, potentially reducing neuroinflammation without immunosuppression [5][6] Research Findings - The loss of synapses in Alzheimer's disease has severe consequences, and XPro™ has shown a robust effect on proteins and pathways that regulate synapse formation [3][4] - The treatment's impact on synaptic proteins aligns with previous observations in preclinical models, suggesting a restoration of normal immune function [3][4] - The company believes that the biological effects observed may lead to cognitive benefits, which are currently being tested in ongoing trials [4]

Company Overview - INmune Bio Inc. is a publicly traded clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease [12] - The company has two product platforms in clinical trials: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform and the Natural Killer Cell Priming Platform [12] - The DN-TNF product platform aims to selectively neutralize soluble TNF, which is a key driver of innate immune dysfunction [12] - XPRO, the first product from the DN-TNF platform, is currently in clinical trials for treating Mild Alzheimer's disease, with plans to explore additional indications such as treatment-resistant depression and oncology [12] - The Natural Killer Cell Priming Platform includes INKmune™, which is designed to prime NK cells for cancer treatment and is currently enrolling patients in a Phase I/II trial for metastatic castrate-resistant prostate cancer [12] Upcoming Events - The company will host a conference call on August 1, 2024, at 4:30 PM EDT to discuss the results for its first quarter ended June 30, 2024, and provide a corporate update [13] - Participants can access the call via a live audio webcast and are encouraged to dial in 5 to 10 minutes before the start time [4][8] - A transcript of the call will be available approximately 24 hours after the event, with a replay accessible until August 8, 2024 [9]

Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics The study demonstrates that memory-like natural killer (mlNK) cells, generated by either cytokine or INKmuneTM priming, show increased cytotoxicity against multiple tumor types, offering promising potential for cancer immunotherapy. Importantly, while most studies are conducted on NK cells from healthy volunteers, this study demonstrated that mlNK fr ...

ipopba INmune Bio, Inc. (NASDAQ:INMB) is a clinical-stage biotechnology company developing immunotherapies for cancer and neuroinflammatory conditions like Alzheimer's disease [AD]. The DN-TNF platform targets soluble TNF, reducing inflammation without disrupting beneficial transmembrane TNF functions crucial for immune regulation and neuroprotection. The NK priming platform improves NK cells' ability to identify and eliminate abnormal cells, transforming them into highly functional, memory-like NK cells. I ...

Exhibit 99.2 INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update Company to Host Conference Call Today, May 9, at 4:30pm ET BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical- stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update. Q1 2024 and Rece ...

Financial Performance - The company reported a net loss of $11.0 million for the three months ended March 31, 2024[113]. - For the three months ended March 31, 2024, the company reported revenues of $14,000, a decrease of 63.16% from $38,000 in the same period of 2023[127]. - The net loss for the three months ended March 31, 2024, was $11.0 million, compared to a net loss of $6.5 million for the same period in 2023, representing an increase of 68.5%[133]. - Total operating expenses for the three months ended March 31, 2024, were $11.0 million, an increase of 70.8% from $6.5 million in the same period of 2023[126]. - The company used approximately $7.5 million in cash for operating activities during the three months ended March 31, 2024, compared to $1.1 million in the same period of 2023[145]. - Cash and cash equivalents decreased to $26.0 million as of March 31, 2024, down from $51.0 million at the end of the same period in 2023[143]. - As of March 31, 2024, the company had cash and cash equivalents of $26.0 million, down from $35.8 million as of December 31, 2023[113]. - The company has incurred losses in each period since inception, raising substantial doubt about its ability to continue as a going concern[114]. Research and Development - The company plans to initiate a Phase II trial for Alzheimer's disease (AD) with 201 patients enrolled in a 2:1 ratio (XPro vs placebo)[108]. - In the Phase I trial for AD, XPro demonstrated a decrease in inflammatory cytokines in the cerebrospinal fluid (CSF) by 84% for neurofilament light chain, 46% for phospho Tau 217, and 91% for VILIP-1 after three months of therapy[107]. - The company received a $2.9 million award from the National Institute of Mental Health (NIMH) to treat treatment-resistant depression (TRD) with XPro[110]. - The Phase I/II trial using INKmune for metastatic castrate-resistant prostate cancer (mCPRC) is expected to be fully enrolled by the first half of 2025, with top-line data available six months later[112]. - The company anticipates significant increases in research and development expenses as it advances more product candidates through clinical development[123]. - Research and development expenses increased to approximately $8.7 million for the three months ended March 31, 2024, compared to $4.1 million for the same period in 2023, reflecting a 111.4% increase[129]. Financing Activities - The company sold 198,364 shares of common stock at an average price of $10.56 for gross proceeds of approximately $2.1 million under the ATM offering from April 4, 2024, to May 6, 2024[134]. - The company raised approximately $4.8 million from the sale of 571,592 shares of common stock and warrants on April 19, 2024[135]. - The company raised approximately $9.7 million from the sale of 986,000 shares of common stock and warrants on April 24, 2024[136]. - The Company repaid $2.5 million of its debt during the three months ended March 31, 2024[147]. Regulatory and Compliance - The company qualifies as an "emerging growth company" under the JOBS Act, allowing for reduced disclosure requirements[115]. - The Company is classified as a "smaller reporting company" and is not required to provide certain market risk disclosures[150]. - There have been no material changes in critical accounting policies and estimates during the three months ended March 31, 2024[148]. Future Plans - The company plans to apply for an accelerated pathway for XPro in 2024, potentially qualifying for Fast Track status[109]. - The company has completed an open-label dose escalation trial for INB03 in cancer patients with metastatic solid tumors, demonstrating safety and pharmacodynamic endpoints[106].

Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced today that it has entered into definitive agreements for the sale and purchase of 986,000 shares of its common stock and warrants to purchase up to an aggregate of 986,000 shares of its common stock at an offering price of $9.84 per share of common stock a ...

Boca Raton, Florida, April 23, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, is delighted to announce the successful completion of the extended stability validation for XProTM continuous storage in solution at 2-8C. The 24 and 30-month stability test samples passed all chemistry and potency assays; allowing the Company to make a conservative claim ...

picturegarden/DigitalVision via Getty Images Topline Summary and Update INmune Bio (NASDAQ:INMB) is a company focused on developing drugs in two different disease areas: neurology and cancer medicine. I've previously covered this company in two articles, and I was a cautious optimist in my latest outing, with main reservations related to their cash burn rate and the challenges of developing drugs for Alzheimer disease, which is their most advanced focus. This article is an update providing a picture of ...

Exhibit 99.1 INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update Company to Host Conference Call Today, March 28, at 4:30pm ET BOCA RATON, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical- stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2023 and provides a business update. Q4 2023 and ...